MIORG Oy is a biotechnology company focused on overcoming resistance to cancer immunotherap
We discover and validate novel immunological targets and translate them into functional therapeutics, including antibodies and peptides, designed to restore responses to anti-PD1 treatments.
Our pipeline already includes a clinically validated prediction model and a preclinically validated combination therapy.
The company operates independently from the Academic Group, with its own research and development activities, while leveraging academic insights when relevant.
Our goal is to enable more patients to benefit from immunotherapy by turning resistance mechanisms into actionable treatments.
Pipeline
VIDEOS
MIORG Oy: Market Potential
Our Research Strategy: